PCSK9 and COVID-19: The main findings of the current study can be summarized as 1) Adding statins to the standard of care did not show any beneficiary effect in improving COVID-19 outcomes, 2) omega-3 fatty acid supplementation resulted in conflicting outcomes which need further evaluation, 3) in only one trial, fibrates had no significant effect on COVID-19 severity, 4) nicotinamide did not affect lymphocyte count in lymphopenic patients with COVID-19, and 5) PCSK9 inhibitors (evolocumab) reduced death rate or the need for intubation in COVID-19 patients.